BioXcel Therapeutics Future Growth

Future criteria checks 3/6

BioXcel Therapeutics is forecast to grow earnings and revenue by 27.2% and 48.8% per annum respectively. EPS is expected to grow by 54% per annum. Return on equity is forecast to be 76.7% in 3 years.

Key information

27.2%

Earnings growth rate

54.0%

EPS growth rate

Biotechs earnings growth	24.0%
Revenue growth rate	48.8%
Future return on equity	76.7%
Analyst coverage	Good
Last updated	26 Apr 2024

Recent future growth updates

Recent updates

BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold

Aug 28

BioXcel Therapeutics Q2 2022 Earnings Preview

Aug 08

BioXcel Therapeutics: BXCL501 For Acute Agitation In Patients With Dementia And Alzheimer's - A Great Asset

Jul 19

BioXcel's Igalmi: Potential Market For Acute Agitation In Esquizofrenia And Bipolar Patients

May 18

Earnings and Revenue Growth Forecasts

NasdaqCM:BTAI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	21	-65	-51	-37	4
12/31/2025	9	-84	-68	-71	7
12/31/2024	3	-97	-84	-91	6
12/31/2023	1	-179	-155	-155	N/A
9/30/2023	1	-212	-167	-167	N/A
6/30/2023	1	-203	-160	-160	N/A
3/31/2023	1	-187	-155	-155	N/A
12/31/2022	0	-166	-135	-135	N/A
9/30/2022	0	-137	-117	-117	N/A
6/30/2022	N/A	-122	-106	-106	N/A
3/31/2022	N/A	-112	-95	-95	N/A
12/31/2021	N/A	-107	-83	-82	N/A
9/30/2021	N/A	-102	-83	-82	N/A
6/30/2021	N/A	-100	-82	-81	N/A
3/31/2021	N/A	-94	-74	-74	N/A
12/31/2020	N/A	-82	-67	-66	N/A
9/30/2020	N/A	-69	-54	-54	N/A
6/30/2020	N/A	-54	-42	-42	N/A
3/31/2020	N/A	-41	-34	-34	N/A
12/31/2019	N/A	-33	-28	-27	N/A
9/30/2019	N/A	-32	-25	-24	N/A
6/30/2019	N/A	-28	-20	-19	N/A
3/31/2019	N/A	-22	-19	-18	N/A
12/31/2018	N/A	-19	-14	-14	N/A
9/30/2018	N/A	-15	-10	-10	N/A
6/30/2018	N/A	-11	-8	-7	N/A
3/31/2018	N/A	-8	-3	-3	N/A
12/31/2017	N/A	-5	-2	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BTAI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BTAI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BTAI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BTAI's revenue (48.8% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: BTAI's revenue (48.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BTAI's Return on Equity is forecast to be very high in 3 years time (76.7%).

BioXcel Therapeutics Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 13%

Price target decreased by 22% to US$7.42

Price target decreased by 8.1% to US$9.50

Price target increased by 8.0% to US$10.80

Consensus revenue estimates increase by 18%

Consensus revenue estimates decrease by 48%, EPS upgraded

Recent updates

BioXcel Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

BioXcel Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Consensus revenue estimates fall by 13%

Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

Price target decreased by 22% to US$7.42

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New major risk - Revenue and earnings growth

BioXcel Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Price target decreased by 8.1% to US$9.50

BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

BioXcel Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $60 million.

Price target increased by 8.0% to US$10.80

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

BioXcel Therapeutics, Inc. Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of Bxcl701 in Combination with Keytruda®

BioXcel Therapeutics, Inc. Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine

New minor risk - Market cap size

Consensus revenue estimates increase by 18%

New major risk - Negative shareholders equity

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

BioXcel Therapeutics, Inc. Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

BioXcel Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Bioxcel Therapeutics, Inc. Receives Permanent J-Code for Igalmi (Dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

BioXcel Therapeutics, Inc. Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (Dexmedetomidine) Sublingual Film

BioXcel Therapeutics, Inc. Announces Board Changes

Independent Chairman & Lead Director notifies of intention to sell stock

Bioxcel Therapeutics, Inc. Receives Notice of Allowance from the U.S. Patent and Trademark Office

Consensus revenue estimates decrease by 48%, EPS upgraded

Rain Oncology Inc., Proterra Inc., Bioxcel Therapeutics, Inc Announces Class Action Update

Jakubowitz Law Reminds BioXcel Shareholders of a Lead Plaintiff Deadline of September 5, 2023

BioXcel Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target increased by 12% to US$48.00

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Bioxcel Therapeutics, Inc

New major risk - Share price stability

BioXcel Therapeutics Announces Positive Topline Results from TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

Price target decreased by 9.4% to US$46.50

BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) dropped from Russell Small Cap Comp Value Index

Founder exercised options and sold US$593k worth of stock

Bioxcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal Security Iii Trial of Bxcl501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia

Founder notifies of intention to sell stock

Consensus revenue estimates decrease by 13%

BioXcel Therapeutics, Inc., Annual General Meeting, Jun 26, 2023

Senior VP & CFO exercised options and sold US$136k worth of stock

BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MAD) Program

Chief Digital Officer ?& Director exercised options and sold US$1.0m worth of stock

Consensus revenue estimates decrease by 26%

Founder notifies of intention to sell stock

Consensus revenue estimates decrease by 11%

Consensus revenue estimates fall by 42%

No longer forecast to breakeven

Forecast to breakeven in 2025

Price target increased by 7.6% to US$54.90

Bioxcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 Asco Genitourinary Cancers Symposium

Price target increased by 9.4% to US$50.78

Insider exercised options and sold US$879k worth of stock

Chief Digital Officer ?& Director exercised options and sold US$1.3m worth of stock

BioXcel Therapeutics, Inc. Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

Founder exercised options and sold US$1.2m worth of stock

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

BioXcel Therapeutics, Inc. Announces First Patients Dosed in Serenity III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

Consensus forecasts updated

Chief Digital Officer ?& Director exercised options and sold US$875k worth of stock

Insufficient new directors

BioXcel Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold

Consensus forecasts updated

Price target decreased to US$49.20